# BluMaiden

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blumaiden

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.blumaiden.com
- Total disclosed funding: $2M
- Latest round: Seed (Jan 13, 2023)
- Investors on record: 3

## About

Founded in 2020 and based in Singapore, BluMaiden is a biotechnology firm that develops illness therapeutics based on the microbiome. As of 2022, Damien Keogh is the CEO of the company. 

The company provides science and technologies including data capture, database, data analytics, and drug discovery. The firm offers services including consumer genomics and digital health, clinical studies, research partnerships, therapeutics, and diagnostics. BluMaiden is developing diagnostics and therapeutics by leveraging DNA sequencing, AI-powered analytics, population-scale precision health data, and novel drug development tools.

## Funding rounds

- Seed, Jan 13, 2023, $1.1M — Mountain Pine Capital
- Seed, Aug 2, 2021, $0.8M — Mountain Pine Capital, Amatar Investment, Tangible Pte Ltd

## Investors

- Mountain Pine Capital (https://capitalatlas.ai/funds/mountain-pine-capital) — Seed
- Amatar Investment — Seed
- Tangible Pte Ltd — Seed